Frontage Laboratories, Inc. has completed GMP validation of its new manufacturing facility, opened in May 2025 and validated in October 2025.
The site is now fully operational, supporting Phase III clinical batches, PPQ activities, and small-scale commercial manufacturing.
What the New Facility Supports?
The facility is designed for end-to-end drug development and manufacturing, covering both clinical and commercial needs.
It supports:
- Sterile dosage forms such as vials, syringes, and cartridges
- Non-sterile products including tablets, capsules, ointments, gels, and oral liquids
- High-potency compounds handled in dedicated containment suites
Manufacturing rooms meet ISO GMP classifications, backed by formulation, analytical, and microbiology laboratories.
Key Equipment Investments
Frontage has significantly expanded its manufacturing infrastructure.
New additions include:
- Three automated aseptic filling lines for vials, syringes, and cartridges
- Two new isolators for potent compound handling and aseptic filling
- Gerties roller compactor for dry granulation
- Korsch tablet press for solid oral dosage forms
- Xcelodose system for precise low-dose filling
- Integrated labeling systems and supporting equipment
These upgrades improve efficiency, quality, and speed to market.
Why This Matters for Pharma Companies?
The expanded facility is built to support:
- Faster clinical trial execution
- Streamlined tech transfer to commercial scale
- Reduced timelines for regulatory-ready manufacturing
This is particularly relevant for small and mid-sized pharma companies targeting rapid development or market entry.
Strategic Impact
By combining advanced manufacturing technology with a comprehensive quality system, Frontage strengthens its position as a full-service CRDMO partner.
The focus is clear: fewer handoffs, faster timelines, and reliable GMP execution.
Leadership Perspective
According to Dr. Song Li, Chairman of Frontage, the facility strengthens Frontage’s ability to manage every stage of pharmaceutical development.
The goal is to help customers optimize both cost and quality, while accelerating patient access to medicines.
About Frontage Laboratories
Frontage Laboratories, Inc. is a US-based global CRDMO and a subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK).
With 26 sites worldwide and over 25 years of experience, Frontage supports drug discovery through commercial manufacturing.
Its services span API synthesis, formulation, GMP manufacturing, clinical trials, bioanalysis, and central lab operations.
